Navigation Links
Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
Date:3/11/2008

BRAINTREE, Mass., March 11 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today the appointment of Peter Allen to the newly created position of Chief Marketing Officer. In this position, Mr. Allen will assume responsibility for global marketing of Haemonetics' full product portfolio in addition to his current responsibilities as President, Donor Division.

Brian Concannon, Chief Operating Officer, commented, "Pete Allen was an architect of our strategic vision to be the global leader in blood management solutions for our customers. He has established strong relationships with our customers and gained keen insight into customer needs and market trends. We are pleased that he will be leading Haemonetics' marketing strategy as we leverage the Haemonetics brand in our expanding markets."

Through its blood management solutions offerings, Haemonetics markets to hospitals, blood banks, and plasma collection customers. Haemonetics' marketing efforts support improving patient care as it relates to blood transfusions while simultaneously reducing total healthcare costs.

Mr. Concannon added, "Haemonetics is uniquely qualified to offer a full suite of business solutions related to blood management. We are the only company that operates across the blood supply chain from the blood donor to the patient transfusion. As importantly, we are the only company that offers the depth of products, through our devices, services, and software solutions, required to truly meet our customers' blood management needs. Under Pete Allen's leadership, we will drive a cohesive, global message of blood management solutions for our customers."

Mr. Allen, age 49, joined Haemonetics in 2003 as President, Donor Division. He has over twenty five years experience in health care and medical products. Prior to joining Haemonetics, Mr. Allen was Vice President of The Aethena Group, a private equity firm providing services to the global healthcare industry. From 1998 to 2001, he held various positions including Vice President of Sales and the Oncology Business at Syncor International, a provider of radiopharmaceutical and comprehensive medical imaging services. Previously, he held executive level positions in sales, marketing and operations in DataMedic, Inc., Enterprise Systems, Inc./HBOC, and Robertson Lowstuter, Inc. Mr. Allen has also worked in sales at American Hospital Supply Corporation and Baxter International, Inc. Mr. Allen is a finance graduate of Lehigh University.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

CONTACT:

Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

fallon@haemonetics.com


'/>"/>
SOURCE Haemonetics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA is inviting ... The new website has been designed to provide the best user-friendly experience coupled ... access detailed product information, read educational industry content as well as share information ...
(Date:12/6/2016)... ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported its financial ... September 30, 2016. ... , SQI is a ... and commercializes proprietary technologies and products for advanced multiplexed diagnostics. ... million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... industrial automation and IT solutions, today announced the company has successfully completed its ... professionally executed automation and control systems integration services to leading companies in life ...
(Date:12/6/2016)... and SAN DIEGO , ... announced the appointment of Santosh Kesari , MD, ... Kesari will leverage his experience in neurology and clinical ... adult stem cell for treatment of stroke. The AmnioStem product ... fluid, which has previously shown therapeutic activity in animal ...
Breaking Biology Technology:
(Date:12/2/2016)... The report "Biometric Vehicle Access ... (Iris Recognition System), Vehicle Type (Passenger Car, Battery ... 2021", published by MarketsandMarkets, the market is estimated ... is projected to grow to USD 854.8 Million ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... Poland , Nov. 30, 2016 Not many of us realize that ... aspects of recovery so we need to do it well. Inadequate sleep levels have ... high blood pressure, stroke, diabetes, and even cancer. Maybe now is the ... present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):